

Product datasheet for TL318860V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

alpha Synuclein (SNCA) Human shRNA Lentiviral Particle (Locus ID 6622)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: alpha Synuclein (SNCA) Human shRNA Lentiviral Particle (Locus ID 6622)

Locus ID: 6622

Synonyms: NACP; PARK1; PARK4; PD1

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: SNCA - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000345, NM 001146054, NM 001146055, NM 007308, NM 000345.1, NM 000345.2,

NM 000345.3, NM 007308.1, NM 007308.2, NM 001146054.1, NM 001146055.1, BC108275,

BC013293, NM 001146054.2, NM 001146055.2, NM 000345.4

UniProt ID: P37840

Summary: Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-

synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and

membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of

Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of

patients with Alzheimer's disease. Alternatively spliced transcripts encoding different

isoforms have been identified for this gene. [provided by RefSeq, Feb 2016]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.




Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.


For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

Product images:




GFP signal was observed under microscope at 48 hours after transduction of TL318860A virus into HEK293 cells. TL318860A virus was prepared using lenti-shRNA TL318860A and [TR30037] packaging kit.






GFP signal was observed under microscope at 48 hours after transduction of TL318860B virus into HEK293 cells. TL318860B virus was prepared using lenti-shRNA TL318860B and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL318860C] virus into HEK293 cells. [TL318860C] virus was prepared using lenti-shRNA [TL318860C] and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL318860D] virus into HEK293 cells. [TL318860D] virus was prepared using lenti-shRNA [TL318860D] and [TR30037] packaging kit.